B

BioMarin Pharmaceutical
D

BMRN

65.680
USD
0.70
(1.07%)
Market Closed
Volume
42,528
EPS
3
Div Yield
-
P/E
40
Market Cap
12,517,492,491
OverviewSignalsIdeasNews
Related Instruments
    AMGN
    AMGN
    2.27
    (0.87%)
    263.46 USD
    BIIB
    BIIB
    -0.780
    (-0.53%)
    146.590 USD
    GILD
    GILD
    1.460
    (1.60%)
    92.570 USD
    I
    INCY
    1.910
    (2.85%)
    68.910 USD
    REGN
    REGN
    -5.64
    (-0.80%)
    702.60 USD
    VRTX
    VRTX
    0.58
    (0.15%)
    397.15 USD
    More
News

Title: BioMarin Pharmaceutical

Sector: Healthcare
Industry: Biotechnology
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.